Jeff Reese
Last active: 1/7/2021

Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation.

Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, Colbran RJ, Reese J, Marnett LJ, Patel S
Nat Neurosci. 2013 16 (9): 1291-8

PMID: 23912944 · PMCID: PMC3788575 · DOI:10.1038/nn.3480

Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatment of affective disorders. Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid to form prostaglandins, but also inactivates eCBs in vitro. However, the viability of COX-2 as a therapeutic target for in vivo eCB augmentation has not been explored. Using medicinal chemistry and in vivo analytical and behavioral pharmacological approaches, we found that COX-2 is important for the regulation of eCB levels in vivo. We used a pharmacological strategy involving substrate-selective inhibition of COX-2 to augment eCB signaling without affecting related non-eCB lipids or prostaglandin synthesis. Behaviorally, substrate-selective inhibition of COX-2 reduced anxiety-like behaviors in mice via increased eCB signaling. Our data suggest a key role for COX-2 in the regulation of eCB signaling and indicate that substrate-selective pharmacology represents a viable approach for eCB augmentation with broad therapeutic potential.

MeSH Terms (26)

Adaptation, Ocular Amidohydrolases Animals Anxiety Benzoxazines Body Temperature Calcium Channel Blockers Cannabinoid Receptor Agonists Cannabinoid Receptor Antagonists Cyclooxygenase 2 Cyclooxygenase Inhibitors Disease Models, Animal Endocannabinoids Exploratory Behavior Freezing Reaction, Cataleptic Humans Indoles Male Maze Learning Mice Mice, Inbred ICR Mice, Knockout Morpholines Naphthalenes Receptor, Cannabinoid, CB1 Signal Transduction

Connections (4)

This publication is referenced by other Labnodes entities: